Liminatus Pharma, Inc. announced a public offering on February 17, 2026, pricing 8,270,000 shares and 5,543,000 pre-funded warrants at $0.29 each, aiming to raise about $3.46 million for R&D and operations. The closing of the offering occurred on February 18, 2026.